Indivior - Overview

Indivior is a pharmaceutical company specialising in addiction treatment. Indivior was spun out of parent Reckitt Benckiser in December 2014. Adding to its Suboxone opioid addiction product, the company has a pipeline including longer-lasting 'depot' formulations, treatments for cocaine intoxication, alcohol addiction and even schizophrenia, as a psychiatric co-morbidity of addiction.

Registrars:

Key Personnel

CEO: Mark Crossley
Chairman: Graham Hetherington
Non-Executive Director: Jerome Lande
Senior Independent Director: Juliet Thompson
Independent Non-Executive Director: Peter Bains, Jo Le Couilliard, Keith Humphreys, Mark Stejbach, David E. Wheadon, Barbara Ryan
CFO & Executive Director: Ryan Preblick

Contact Details

Address: 234 Bath Road, Slough, Berkshire, United Kingdom
Phone:
Fax:
Website: http://www.Indivior.com
Email:

Listings

ISIN: GB00BN4HT335
Sector: Pharma and Biotech, Pharma and Biotech
Main Indices: FTSE 250, FTSE 350, FTSE All-Share